Status:
COMPLETED
Ziprasidone in the Psychosis Prodrome
Lead Sponsor:
Yale University
Conditions:
Psychosis Prodrome
Eligibility:
All Genders
16-40 years
Phase:
PHASE2
Brief Summary
This study aims to determine whether ziprasidone is superior to placebo over 24 weeks for patients with the psychosis prodrome.
Eligibility Criteria
Inclusion
- Structured Interview for Psychosis-risk Syndromes criteria for Clinical High Risk for Psychosis
- clinically referred
Exclusion
- prolonged corrected QT interval
- history of syncope
Key Trial Info
Start Date :
March 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2012
Estimated Enrollment :
51 Patients enrolled
Trial Details
Trial ID
NCT00635700
Start Date
March 1 2008
End Date
November 1 2012
Last Update
March 27 2023
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California at San Diego
La Jolla, California, United States, 92093
2
University of California at Los Angeles
Los Angeles, California, United States, 90095
3
University of California, San Francisco
San Francisco, California, United States, 94143
4
Yale University School of Medicine
New Haven, Connecticut, United States, 06519